PSMA PET/CT Scan Indications for Newly Diagnosed Prostate Cancer

Risk-Based Approach to Imaging

The European Association of Urology recommends PSMA PET/CT scanning for newly diagnosed prostate cancer patients with high-risk disease features, while patients with low or favorable intermediate-risk disease generally do not require this advanced imaging 1, 2
Conventional imaging is not recommended for asymptomatic patients with low-risk prostate cancer as the probability of nodal or distant metastasis is very low, according to the Journal of Urology 2, 3
The European Urology guidelines state that PSMA PET/CT is not indicated in low-risk disease population due to low yield and unnecessary cost 1, 4
For unfavorable intermediate-risk disease, the European Urology guidelines suggest considering cross-sectional abdominopelvic imaging and bone scan 1
PSMA PET/CT may be considered in unfavorable intermediate-risk patients if available, though evidence is still evolving, as stated by the European Urology and Journal of Urology guidelines 1, 5

All patients with high-risk disease should undergo metastatic screening with PSMA PET/CT if available, according to the European Urology guidelines 1
If PSMA PET/CT is not available, conventional imaging with bone scan plus either pelvic mpMRI or CT scan is strongly recommended by the Journal of Urology and European Urology guidelines 2, 3
High-risk features include PSA levels above a certain threshold, high Gleason scores, or advanced clinical stages, as defined by the Journal of Urology and European Urology guidelines 2, 6

PSMA PET/CT has demonstrated greater accuracy than conventional imaging in detecting nodal and distant metastases in high-risk prostate cancer, with a reported accuracy of 27% greater than conventional imaging, according to the European Urology and Journal of Urology guidelines 1, 2
The sensitivity of PSMA PET/CT for nodal metastases is significantly higher than conventional imaging, with a sensitivity of 85% compared to 38% for conventional imaging, as reported by the European Urology guidelines 1
The specificity of PSMA PET/CT is also superior to conventional imaging, with a specificity of 98% compared to 91% for conventional imaging, according to the European Urology guidelines 1
PSMA PET/CT leads to management changes in approximately 28% of high-risk patients compared to 15% with conventional imaging, as stated by the European Urology guidelines 1

For patients with low PSA levels and low-grade disease, no imaging is typically needed, according to the Praxis Medical Insights guidelines, however this fact is not preferred as it is from Praxis Medical Insights 6
For patients with high PSA levels, PSMA PET/CT is strongly recommended if available; otherwise, bone scan and CT/MRI are recommended by the European Urology guidelines 1
Regardless of PSA level, patients with high Gleason scores or advanced clinical stages should undergo PSMA PET/CT or conventional imaging, as recommended by the Journal of Urology and European Urology guidelines 1, 2

PSMA PET/CT exposes patients to less radiation than conventional imaging, with a reported radiation exposure of 8.4 mSv compared to 19.2 mSv for conventional imaging, according to the European Urology guidelines 1
PSMA PET/CT results in fewer equivocal findings compared to conventional imaging, with a reported rate of 7% compared to 23% for conventional imaging, as stated by the European Urology guidelines 1